CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
gemcitabine, epirubicin, paclitaxeldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00378313
NCT00378313Phase 2Completed

A Phase 2 Study of Neoadjuvant Chemotherapy With Gemcitabine, Epirubicin and Paclitaxel (Taxol)[GET] in Locally Advanced Breast Cancer

NSABP Foundation Inc·interventional·Posted Sep 19, 2006·Updated Nov 26, 2008

In Brief

A Phase 2 clinical trial evaluating gemcitabine, epirubicin, paclitaxel for Stage IIB Breast Cancer and 5 related conditions. Completed, across 1 site.

Detailed Summary

The primary purpose of this study is to determine whether locally advanced breast cancer responds (by shrinking, by not progressing or by being destroyed) to combined chemotherapy (gemcitabine, epirubicin and paclitaxel) given before surgery to patients with locally advanced breast cancer. This study will also evaluate the toxicity of the chemotherapy combination to patients and will determine survival and progression-free survival 2 years after treatment. Also, the study will look at whether there are molecular and genetic changes in the tumor tissue that match the tumor's response to the chemotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 19, 2006
Enrollment StartNov 1, 2001
Study CompletionNov 1, 2005
TodayJul 1, 2026
Posted 19.8 years ago

Interventions

gemcitabine, epirubicin, paclitaxeldrug